Poster presented at EBF, Barcelona 2022
Strategies for measuring oligonucleotides using a fully automated microfluidic immunoassay system
The rapidly growing field of oligonucleotide medicine provides unique opportunities to treat genetic diseases and provide new treatment and vaccines for viral diseases. As of 2021, there are 15 FDA approved oligonucleotide-based drugs (excluding vaccines), and many more are currently in clinical trials. These drugs are often structural variants of DNA or RNA which increases resilience, uptake and target affinity. Pharmacokinetic (PK) and pharmacodynamic (PD) measurements of these drugs in clinical trials can be performed by utilizing the base pairing capabilities in hybridization assays which mimic an ELISA format. However, these methods are often time and labor intensive. Hence, transferring such methods to an automated microfluidics system as described in this study could potentially increase throughput and decrease runtime.